On the basis of this observation, we deduced that in addition to the role of dCK in gemcitabine metabolism, this kinase may also contribute to drug resistance by regulating ROS production and the NRF2/ARE axis, which synergistically regulate intrinsic and acquired gemcitabine resistance in pancreatic cancer cells. This evidence concerns the gene NFE2L2 and familial pancreatic carcinoma.